See All Slides -

Slides

Presentation TCT 2012

Proinflammatory Responses and Acute Tissue Injury

Presenter: Jan Piek

October 22, 2012

Presentation TCT 2012

Dedicated Bifurcation Stents: Minvasys Nile Program Update

Presenter: Roxana Mehran

October 22, 2012

$Mobilized CD 34+ Cells for Refractory Angina$

Presentation TCT 2012

Mobilized CD 34+ Cells for Refractory Angina

Presenter: Thomas Povsic

October 22, 2012

Presentation TCT 2012

Role of FFR in Globally Balanced Myocardial Ischemia : Falsely Negative 99mTc Scintigram Associated with highly significant FFR

Presenter: Anupam Bhambhani

October 22, 2012

Presentation TCT 2012

My Criteria for Selecting Transapical TAVR (vs. Transfemoral TAVR or Open Surgery)

Presenter: Rudiger Lange

October 22, 2012

Presentation TCT 2012

SUPPORT-1: A Prospective, Randomized Trial of a Lipoic Acid-Based Cytoprotectant in Patients Undergoing Elective PCI

Presenter: Mitchell Krucoff

October 22, 2012

Presentation TCT 2012

New Pacemakers After TAVR: Frequency, Predictors, Clinical Outcomes, and Guidelines on “When to Treat”

Presenter: Jeffrey Popma

October 22, 2012

Presentation TCT 2012

Mitral Valve Disease Hemodynamics, Balloon Valvuloplasty and the Edge-to-Edge Approach (Including Related Guidelines)

Presenter: Zoltan Turi

October 22, 2012

Presentation TCT 2012

“Nuggets” on Patient Selection After > 1,000 TAVR Cases (Performed and/or Proctored): Self-Expanding TAVR

Presenter: Ganesh Manoharan

October 22, 2012

Presentation TCT 2012

An Overview of TAVR Complications from a Meta-analysis Using VARC Definitions

Presenter: Philippe Genereux

October 22, 2012

Advertisement

Slides

Proinflammatory Responses and Acute Tissue Injury

Dedicated Bifurcation Stents: Minvasys Nile Program Update

Mobilized CD 34+ Cells for Refractory Angina

Role of FFR in Globally Balanced Myocardial Ischemia : Falsely Negative 99mTc Scintigram Associated with highly significant FFR

My Criteria for Selecting Transapical TAVR (vs. Transfemoral TAVR or Open Surgery)

SUPPORT-1: A Prospective, Randomized Trial of a Lipoic Acid-Based Cytoprotectant in Patients Undergoing Elective PCI

New Pacemakers After TAVR: Frequency, Predictors, Clinical Outcomes, and Guidelines on “When to Treat”

Mitral Valve Disease Hemodynamics, Balloon Valvuloplasty and the Edge-to-Edge Approach (Including Related Guidelines)

“Nuggets” on Patient Selection After > 1,000 TAVR Cases (Performed and/or Proctored): Self-Expanding TAVR

An Overview of TAVR Complications from a Meta-analysis Using VARC Definitions

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content